In non-small-cell lung cancer (NSCLC), a cold tumor immunological microenvironment, i.e., lower infiltration of CD3+ T cells and lower concentration of various immune signatures, correlated with a high chromosomal copy number variant (CNV) burden was associated with a lower benefit of ICIs, whereas a greater proximity of CD8+GZB+ T cells to malignant cells influenced the benefit of ICI therapy [92]. The gene discussed is CD8A; the disease is non-small cell lung carcinoma.